Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs International Business Machines Corp (IBM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs International Business Machines Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while International Business Machines Corp trades at $288.9 (market cap $270.27B). The key difference: International Business Machines Corp is far larger — about 6.8× Alnylam Pharmaceuticals, Inc.'s market cap, and International Business Machines Corp pays a 2.35% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | IBM | |
|---|---|---|
Market Cap | $39.89B | $270.27B |
Sector | Health | Technology |
52-Week High | $491.22 | $329.23 |
52-Week Low | $278.09 | $214.64 |
Enterprise Value | $38.15B | $328.29B |
Volume | — | 4,481,527 |
Dividend Yield | — | 2.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
IBM trades at $287.56, down 2.62% today, near key support at $288. The stock shows strong fundamentals with revenue growth to $67.54B in 2025 and net income margin of 15.61%. Recent quarterly earnings consistently beat estimates, and the technical outlook is bullish with moving averages signaling upward momentum. Analyst consensus price target is $309.07, suggesting potential upside from current levels.
Outlook remains positive driven by enterprise AI and quantum computing initiatives, though risks include competitive pressures in software and reliance on legacy systems. Wall Street sentiment is mixed with 47% buy ratings, but institutional interest remains strong. The upcoming Q2 2026 earnings report on July 22 will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About International Business Machines Corp
International Business Machines Corporation (IBM) provides computer solutions. The Company offers application, technology consulting and support, process design and operations, cloud, digital workplace, and network services, as well as business resiliency, strategy, and design solutions. IBM serves clients worldwide.
Read more on IBM →
